83 related articles for article (PubMed ID: 18841151)
21. Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib.
Powles T; Chowdhury S; Shamash J; Bazeos A; Gillessen S; Saunders N; Lim L; Sarwar N; Sadev A; Wilson P; Nathan P; Boleti K; Peters J; Agrawal S
Ann Oncol; 2011 Apr; 22(4):815-820. PubMed ID: 20943595
[TBL] [Abstract][Full Text] [Related]
22. The Surge in the Number of Circulating Tumor Cells Following Treatment with Sunitinib for Metastatic Renal Cell Carcinoma.
Nagaya N; Kanayama M; Nagata M; Horie S
Intern Med; 2018 Sep; 57(18):2695-2700. PubMed ID: 29709937
[TBL] [Abstract][Full Text] [Related]
23. Sunitinib-induced severe hypoglycemia in a diabetic patient.
Demirci A; Bal O; Durnali A; Ekinci AŞ; Eşbah O; Alkiş N; Oksüzoğlu B
J Oncol Pharm Pract; 2014 Dec; 20(6):469-72. PubMed ID: 24158980
[TBL] [Abstract][Full Text] [Related]
24. Sunitinib and improved diabetes control.
Tyrrell HE; Pwint T
BMJ Case Rep; 2014 Dec; 2014():. PubMed ID: 25540214
[TBL] [Abstract][Full Text] [Related]
25. Remission of diabetes while on sunitinib treatment for renal cell carcinoma.
Templeton A; Brändle M; Cerny T; Gillessen S
Ann Oncol; 2008 Apr; 19(4):824-5. PubMed ID: 18326519
[No Abstract] [Full Text] [Related]
26. Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.
Diekstra MH; Fritsch A; Kanefendt F; Swen JJ; Moes D; Sörgel F; Kinzig M; Stelzer C; Schindele D; Gauler T; Hauser S; Houtsma D; Roessler M; Moritz B; Mross K; Bergmann L; Oosterwijk E; Kiemeney LA; Guchelaar HJ; Jaehde U
CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):604-613. PubMed ID: 28571114
[TBL] [Abstract][Full Text] [Related]
27. [Hematologic adverse effects in patients with renal cell carcinoma treated with sunitinib].
Hong YP; Yao XD; Zhu Y; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu YP; Ma CG; Xiao WJ; Qin XJ; Lin GW; Ye DW
Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(12):902-5. PubMed ID: 23863673
[TBL] [Abstract][Full Text] [Related]
28. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels.
Kappers MH; van Esch JH; Sluiter W; Sleijfer S; Danser AH; van den Meiracker AH
Hypertension; 2010 Oct; 56(4):675-81. PubMed ID: 20733093
[TBL] [Abstract][Full Text] [Related]
29. Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma.
Patard JJ; Thuret R; Raffi A; Laguerre B; Bensalah K; Culine S
Eur Urol; 2009 Jan; 55(1):237-9; quiz 239. PubMed ID: 18804907
[TBL] [Abstract][Full Text] [Related]
30. Sunitinib does not block thyroid peroxidase in patients.
Liwanpo L; Ro C; Haq S; Hershman JM
Thyroid; 2014 Aug; 24(8):1325-6. PubMed ID: 24521256
[No Abstract] [Full Text] [Related]
31. The early effect of sunitinib on insulin clearance in patients with metastatic renal cell carcinoma.
Thijs AM; Tack CJ; van der Graaf WT; Rongen GA; van Herpen CM
Br J Clin Pharmacol; 2016 Apr; 81(4):768-72. PubMed ID: 26447463
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma.
Chen J; Wang C; Han J; Luan Y; Cui Y; Shen R; Sha D; Cong L; Zhang Z; Wang W
Expert Rev Anticancer Ther; 2013 Jun; 13(6):737-43. PubMed ID: 23573816
[TBL] [Abstract][Full Text] [Related]
33. Development of a validated LC-MS/MS method for the in vitro and in vivo quantitation of sunitinib in glioblastoma cells and cancer patients.
Chatziathanasiadou MV; Stylos EK; Giannopoulou E; Spyridaki MH; Briasoulis E; Kalofonos HP; Crook T; Syed N; Sivolapenko GB; Tzakos AG
J Pharm Biomed Anal; 2019 Feb; 164():690-697. PubMed ID: 30472587
[TBL] [Abstract][Full Text] [Related]
34. Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy.
Stachyra-Strawa P; Szatkowska-Sieczek L; Cisek P; Gołębiowski P; Grzybowska-Szatkowska L
Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397167
[TBL] [Abstract][Full Text] [Related]
35. Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review.
Mugiya T; Mothibe M; Khathi A; Ngubane P; Sibiya N
Front Pharmacol; 2024; 15():1355171. PubMed ID: 38362147
[TBL] [Abstract][Full Text] [Related]
36. Approach to the Patient: Insulinoma.
Hofland J; Refardt JC; Feelders RA; Christ E; de Herder WW
J Clin Endocrinol Metab; 2024 Mar; 109(4):1109-1118. PubMed ID: 37925662
[TBL] [Abstract][Full Text] [Related]
37. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management.
Shyam Sunder S; Sharma UC; Pokharel S
Signal Transduct Target Ther; 2023 Jul; 8(1):262. PubMed ID: 37414756
[TBL] [Abstract][Full Text] [Related]
38. Tyrosine Kinase Targeting: A Potential Therapeutic Strategy for Diabetes.
Althubiti M
Saudi J Med Med Sci; 2022; 10(3):183-191. PubMed ID: 36247049
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib decreases glycemia by impairing hepatic glucose metabolism.
Ma J; Sui F; Liu Y; Yuan M; Dang H; Liu R; Shi B; Hou P
Endocrine; 2022 Dec; 78(3):446-457. PubMed ID: 36205915
[TBL] [Abstract][Full Text] [Related]
40. Insulin Resistance and Pellino-1 Mediated Decrease in the Activities of Vasodilator Signaling Contributes to Sunitinib-Induced Hypertension.
Liu Y; Tang LL; Liang C; Wu MM; Zhang ZR
Front Pharmacol; 2021; 12():617165. PubMed ID: 33841146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
